RET and thyroid gland carcinoma: Pralsetinib, another potent, selective RET inhibitor, was also shown to have clinically meaningful activity in RET fusion-positive thyroid cancer with an ORR of 89% (8 of 9 patients) (Subbiah et al. 2021a, Mansfield et al. 2022).